ROTE WILLIAM E. 4

What Happened

• William E. Rote, Chief Research Officer of Travere Therapeutics (TVTX), sold 12,446 shares in an open-market transaction on Feb 3, 2026 for $32.87 per share, totaling $409,100. On Jan 31, 2026 he was also granted 20,090 restricted stock units (RSUs) and a separate derivative award of 53,570 units (both reported at $0.00 acquisition price).

Key Details

• Sale: 12,446 shares on 2026-02-03 at $32.87 — proceeds $409,100. (Footnote F2: sale made under a written 10b5-1 plan and includes shares sold to cover tax withholding from RSU vesting.)
• Grants (reported 2026-01-31): 20,090 RSUs (each RSU represents a contingent right to one share; Footnote F1) and a derivative award of 53,570 units (Footnote F3 describes vesting: 25% after one year, then monthly over 36 months).
• Shares owned after the transactions are not specified in the provided excerpt of the Form 4.
• Filing: Form 4 was filed on 2026-02-03 reporting the above transactions.

Context

• The sale appears routine: footnote indicates it was executed under a pre-established Rule 10b5-1 plan and was used to satisfy tax withholding related to RSU vesting. The grants are awards (acquisitions) that vest over time; the derivative award follows a standard vesting schedule rather than an immediate market sale. These disclosures are factual record of insider activity and do not by themselves indicate management sentiment.